Taking full advantage of the stock market and investing with confidence are common goals for new and old investors, and Zacks Premium offers many different ways to do both.The research service features daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, all of which will help you become a smarter, more confident investor.It also includes access to the Zacks Style Scores.What are the Zacks Style Scores?Developed a ...

The biotechnology sector is renowned for its potential to deliver groundbreaking medical treatments while offering investors the possibility of significant returns. However, investing in these companies requires a nuanced understanding of their pipelines, regulatory landscapes and market dynamics. Identifying biotech stocks to double your money is certainly no easy feat. But looking at companies with late-stage drug approval potential and market dominance in their respective fields is a great start. While b ...

Investors seek growth stocks to capitalize on above-average growth in financials that help these securities grab the market's attention and produce exceptional returns. However, it isn't easy to find a great growth stock.By their very nature, these stocks carry above-average risk and volatility. Moreover, if a company's growth story is over or nearing its end, betting on it could lead to significant loss.However, the task of finding cutting-edge growth stocks is made easy with the help of the Zacks Growth S ...

It doesn't matter your age or experience: taking full advantage of the stock market and investing with confidence are common goals for all investors. Luckily, Zacks Premium offers several different ways to do both.Featuring daily updates of the Zacks Rank and Zacks Industry Rank, full access to the Zacks #1 Rank List, Equity Research reports, and Premium stock screens, the research service can help you become a smarter, more self-assured investor.It also includes access to the Zacks Style Scores.What are th ...

United Therapeutics‘ (UTHR) first-quarter 2024 earnings of $6.17 per share beat the Zacks Consensus Estimate of $5.63. Earnings rose 27% year over year on the back of higher product sales.Revenues were $677.7 million, which beat the Zacks Consensus Estimate of $628 million. Revenues rose 34% year over year, driven by meaningful growth of all key products — Tyvaso, Orenitram, Remodulin and Unituxin.Quarter in DetailUnited Therapeutics markets four products for pulmonary arterial hypertension (PAH) — Remoduli ...

United Therapeutics Corporation (NASDAQ:UTHR) Q1 2024 Earnings Conference Call May 1, 2024 9:00 AM ET Company Participants Dewey Steadman - Head of Investor Relations Martine Rothblatt - Chairperson and Chief Executive Officer Michael Benkowitz - President and Chief Operating Officer James Edgemond - Chief Financial Officer and Treasurer Leigh Peterson - Executive Vice President-Product Development and Xenotransplantation Conference Call Participants Terence Flynn - Morgan Stanley Roanna Ruiz - Leerink Ash ...

United Therapeutics (UTHR) reported $677.7 million in revenue for the quarter ended March 2024, representing a year-over-year increase of 33.7%. EPS of $6.17 for the same period compares to $4.86 a year ago.The reported revenue represents a surprise of +7.96% over the Zacks Consensus Estimate of $627.72 million. With the consensus EPS estimate being $5.63, the EPS surprise was +9.59%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to ...

SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., May 1, 2024: United Therapeutics Corporation (Nasdaq: UTHR), a public benefit corporation, today announced its financial results for the quarter ended March 31, 2024. Total revenues in the first quarter of 2024 grew 34 percent year-over-year to $677.7 million, compared to $506.9 million in the first quarter of 2023. "The first quarter of 2024 represents another quarter of record revenue and double-digit year-over-year revenue growth," jointly said Martine ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the transition period from to Commission file number 0-26301 United Therapeutics Corporation (Exact Name of Registrant as Specified in Its Charter) Delaware 52-19847 ...

United Therapeutics (UTHR) could be a solid choice for investors given its recent upgrade to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of the most powerful forces impacting stock prices.The sole determinant of the Zacks rating is a company's changing earnings picture. The Zacks Consensus Estimate -- the consensus of EPS estimates from the sell-side analysts covering the stock -- for the current and following years is tracked by the system.The ...